Document:

exv10w46

 

EXHIBIT 10.46

TERMINATION AND TRANSITION

AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT

     THIS Amendment (the “Amendment”) to the Collaboration and License
Agreement by and between Altus Pharmaceuticals, Inc. (“Altus”) and
Genentech, Inc. (“Genentech”) dated December 19, 2006 (the “Agreement”) is
made and entered into by Altus and Genentech effective as of December 19, 2007 (the “Amendment
Effective Date”). Altus and Genentech may each be referred to as a “Party” or together, the
“Parties”.

     Whereas, Altus and Genentech are parties to the Agreement, the Effective Date (as
defined therein) of which is February 21, 2007; and

     Whereas, Altus and Genentech desire to terminate the Agreement and provide for the
orderly transition of activities in connection with such termination;

     Now, Therefore, in consideration of the foregoing premises, Altus and Genentech
hereby agree as follows:

1. Definitions. All capitalized terms not expressly defined in this Amendment shall have the
meaning assigned to them in the Agreement.

2. Termination. The Parties hereby agree to terminate the Agreement effective as of December 31,
2007 (the “Termination Date”). The Parties agree to continue to perform their respective
responsibilities under the Agreement through the Termination Date, including (i) any obligations
under the Agreement to pay Development Costs [*****] prior to the Termination Date; and (ii)
Genentech to be responsible for the [*****] Compound provided to Althea prior to the [*****].
Genentech shall pay Altus all invoiced and [*****] incurred prior to [*****] within [*****] days of
the Amendment Effective Date. Only those rights and obligations expressly set forth in this
Amendment shall extend beyond the Termination Date. As of the Termination Date, all Products shall
be deemed “Termination Products” under the Agreement. Subject to the rights and licenses granted
to Altus hereunder, Altus shall have the right to use all Termination Product and Compound in
inventory at Althea Technologies, Inc. (“Althea”) as of the Termination Date for on-going
manufacturing, clinical and development activities.

3. Conduct of the Development Plan; Transition.

     (a) Subject to Section 12.9 of the Agreement, Genentech shall provide Altus, within [*****]
days following the Termination Date, with respect to those Termination Products existing as of the
Termination Date, copies of any data and materials Controlled

Portions of this Exhibit were omitted, as indicated by [*****], and have been filed separately with the Secretary of the

Commission pursuant to the Registrant’s application requesting confidential treatment under

Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

1

 

by Genentech and made or developed in the course of developing Termination Products hereunder
that are necessary for the continued development or commercialization of such Termination Products
(including any information regarding safety, efficacy, toxicity, and potential side effects). In
addition, and also subject to Section 12.9 of the Agreement, Genentech shall, upon Altus’ written
request, provide Altus, and/or a Third Party Collaborator (as defined below) designated by Altus,
with a right of reference to the applicable drug master files, or the equivalent, necessary to
obtain or maintain Marketing Authorizations for any Termination Product. The Parties agree to
cooperate and to exercise Commercially Reasonable Efforts to assure the transfer of the foregoing
in a manner that facilitates a smooth and orderly transition of development responsibility for such
Products from Genentech to Altus.

     (b) Subject to Section 12.9 of the Agreement and any licenses or sublicenses granted by
Genentech to a Third Party, as of the Termination Date Genentech grants to Altus a non-exclusive,
non-sublicensable (except as explicitly set forth below), non-transferable license under the
Genentech Technology and Genentech Collaboration Technology as necessary to make, have made, use,
sell, offer for sale and import the Termination Product. The foregoing license to Altus under the
Genentech Collaboration Technology shall be sublicensable by Altus to third parties who are
collaborators on the development and/or commercialization of Termination Products with Altus or
licensees of Termination Products of Altus with respect to Termination Products, each pursuant to a
written agreement governing such collaboration or license and the sublicense of Genentech
Collaboration Technology (a “Third Party Collaborator”). For avoidance of doubt, Altus may supply
Compound to a Third Party Collaborator for the purpose of manufacturing a Termination Product.

     (c) Genentech shall supply Altus with such quantities of Compound as are [*****] for Altus to
[*****] at [*****], namely the [*****] provided for in the agreement with [*****] as of the
Termination Date; provided that Altus shall provide Genentech with at least [*****] prior notice
for quantities of Compound in excess of the [*****] currently in [*****]. Altus will reimburse
Genentech for supply of Compound under this Section 3(c) of the Amendment at a rate of [*****] of
Genentech’s [*****] within [*****] following the receipt by Altus of an invoice for such amounts.
As of December 18, 2007, Genentech estimates its [*****] at approximately [*****]. The Parties
acknowledge and agree that Genentech’s [*****] is subject to change consistent with the definition
under [*****] of the Agreement.

4. Long Term Supply. In addition to the supply commitment set forth in Section 3(c) above,
Genentech shall supply Altus with Compound which, as of the Termination Date, is [*****] by
Genentech, pursuant to a written supply agreement, for each of the Option and Licensed Territories
as follows:

     (a) Option Territory. Genentech will supply Altus with clinical requirements of
Compound for the Option Territory for a period of no longer than [*****] from Termination Date and
commercial requirements for the Option Territory for a period of no longer than [*****] from
receipt of the first Marketing Authorization for Product outside the Licensed Territory. Altus
shall reimburse Genentech for such supply of

Portions of this Exhibit were omitted, as indicated by [*****], and have been filed separately with the Secretary of the

Commission pursuant to the Registrant’s application requesting confidential treatment under

Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

2

 

Compound under this subsection (a) at a cost to be negotiated no less than Genentech’s [*****]
and [*****].

     (b) Licensed Territory. Genentech shall supply Altus with clinical requirements of
Compound for the Licensed Territory for a period of no longer than [*****] from the Termination
Date. Altus shall reimburse Genentech for such supply of Compound under this subsection (b) at a
cost to be negotiated no less than Genentech’s [*****] and [*****].

     (c) The foregoing clinical and/or commercial requirements of Altus may include the
requirements of Altus’ licensee(s)’ (including sublicensees as permitted hereunder).
Notwithstanding Section 3(b) of this Amendment, and for clarity, Third Party Collaborators may
develop and commercialize Termination Products manufactured using Compound supplied by Genentech to
Altus pursuant to this Amendment, subject to the terms of this Amendment, including, without
limitation Section 12.9 of the Agreement.

     (d) The Parties agree to use [*****] to enter into the foregoing written supply agreement
consistent with subsections (a) and (b) above and containing other reasonable and customary terms
and conditions within [*****] of the Termination Date.

5. Termination Compensation. In addition, Genentech shall, within [*****] of the Amendment
Effective Date, pay Altus Four Million Dollars (US $4,000,000).

For avoidance of doubt, except for the payments provided under this Section, Genentech shall have
no further obligation for Development Costs, or any other costs or expenses, under the Agreement
after the Termination Date.

6. Release.

     (a) Mutual Release. Effective on the Termination Date, each Party, and each of their
respective successors and assigns, hereby now and forever releases and discharges the other Party
and its Affiliates, and each of their respective successors and assigns, and past and present
officers, directors, employees, agents, attorneys, representatives and trustees, from any and all
causes of action, actions, claims, and demands whatsoever, in law or in equity (collectively,
“Claims”), which such Party had, have or may have based on occurrences up to and including the
Termination Date, and any liabilities, losses, damages, costs and expenses related thereto
(collectively, “Liabilities”). For the avoidance of doubt, this mutual release does not relieve or
release either Party from Claims or Liabilities from obligations surviving under the Agreement or
obligations under this Amendment, provided, in each case, such Claims or Liabilities are based on
occurrences following the Termination Date.

     (b) Waiver Of California Civil Code Section 1542. Each Party acknowledges familiarity
with the provisions of Section 1542 of the California Civil Code and expressly waives and releases
any rights or benefits arising thereunder. Section 1542 of the California Civil Code states:

Portions of this Exhibit were omitted, as indicated by [*****], and have been filed separately with the Secretary of the

Commission pursuant to the Registrant’s application requesting confidential treatment under

Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

3

 

“A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of
executing the release, which if known by him must have materially
affected his settlement with the debtor.”

7. Survival. In addition to the terms set forth in this Amendment, the provisions of ARTICLE I,
2.3(c), 2.4, 2.5, 5.74, ARTICLE X (except Section 10.11.1; and provided that Sections 10.1.3(b)
and 10.5.4 survive solely with respect to any Collaboration Technology existing as of the
Termination Date), Section 12.9, ARTICLE XIII, ARTICLE XIV, ARTICLE XV, and Sections 16.2, 16.3,
16.5, 16.6, 16.7, 16.9 and 16.10 shall survive termination of the Agreement, but in all cases shall
be interpreted to exclude the subject matter of non-surviving terms. In addition, Altus’
obligation to pay Royalties under Section 12.9 on Termination Product shall survive termination of
the Agreement. For clarity, Section 13.2(b) of the Agreement is hereby amended and restated in its
entirety to say “(b) the activities performed by or on behalf of Altus in connection with the
exercise of its licenses and rights under this Agreement, or any Amendment hereto, including Altus’
or its licensees’ or sublicenses’ use of Compound supplied by Genentech, or the development,
manufacture, or commercialization of any Termination Product by Altus or its licensees or
sublicensees.”

8. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

[Remainder of Page Intentionally Left Blank]

Portions of this Exhibit were omitted, as indicated by [*****], and have been filed separately with the Secretary of the

Commission pursuant to the Registrant’s application requesting confidential treatment under

Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

4

 

In Witness Whereof, the parties hereto have executed this Amendment as of the
date last written below.

	 	 	 	 	 	 	 	 	 	 	 
	Altus Pharmaceuticals, Inc.	 	 	 	Genentech, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Sheldon Berkle	 	 	 	By:
	 	/s/ David Ebersman	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Name:

	 	Sheldon Berkle
	 	 	 	Name:
	 	David Ebersman	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:

	 	President and CEO
	 	 	 	Title:
	 	EVP and CFO	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	12/19/2007
	 	 	 	Date:
	 	12/19/07	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

Portions of this Exhibit were omitted, as indicated by [*****], and have been filed separately with the Secretary of the

Commission pursuant to the Registrant’s application requesting confidential treatment under

Rule 24b-2 of the Securities Exchange Act of 1934, as amended.exv10w50

 

EXHIBIT 10.50

MANUFACTURING LICENSE, OPTION

AND SUPPORT AGREEMENT

between

AMANO ENZYME, INC.

and

ALTUS PHARMACEUTICALS INC.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

 

 

MANUFACTURING LICENSE, OPTION

AND SUPPORT AGREEMENT

     MANUFACTURING LICENSE, OPTION AND SUPPORT AGREEMENT dated as of December 20, 2007 (the
“Effective Date”) between AMANO ENZYME, INC., a corporation organized and existing under the laws
of Japan, having its principal place of business at 1-2-7, Nishiki, Naka-ku, Nagoya, Japan
(hereinafter referred to as “Amano”) and ALTUS PHARMACEUTICALS INC., a Delaware corporation having
its principal place of business at 125 Sidney Street, Cambridge, Massachusetts 02110, USA
(hereinafter referred to as “Altus”).

INTRODUCTION

     Altus and Amano entered into a Cooperative Development Agreement dated as of November 2002, as
amended (as so amended, the “Development Agreement”), pursuant to which the Parties cooperatively
developed certain enzyme materials for Altus’ pharmaceutical product known as TrizytecTM
[porcine-free enzyme] (formerly referred to as TheraCLECTM Total and ALTU-135). Pursuant to the
Development Agreement, (i) the Parties contemplated providing to each other support in certain
areas, (ii) Amano agreed to grant certain licenses to its technology to Altus for the purposes of
manufacturing Trizytec, and (iii) it was anticipated that Amano would be granted an option to
supply certain enzyme materials for Trizytec for commercial and clinical purposes.

     The Parties now desire to set forth the specific terms of such license, support and option.

     In consideration of the mutual covenants and promises contained in this Agreement and other
good and valuable consideration, Amano and Altus agree as follows:

Article I. DEFINITIONS

     As used in this Agreement, the following terms, whether used in the singular or plural, shall
have the following meanings:

     “Affiliate” means any corporation, company, partnership, joint venture and/or firm which
controls, is controlled by or is under common control with a Party. For purposes hereof, “control”
shall mean (a) in the case of corporate entities, direct or indirect ownership of at least 50% of
the stock or shares entitled to vote for the election of directors; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least 50% of the equity interest with
the power to direct the management and policies of such non-corporate entities.

     “Altus Know-How” means all materials and information now owned and hereinafter acquired or
solely developed by Altus relating to the making, using and selling of the Materials.

     “Altus Patent Rights” means all patents and patent applications now owned or controlled

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

 

 

or
hereinafter owned or acquired or solely developed by Altus relating to making, using and selling of
the Materials.

     “Altus Technology” means any and all technologies now owned and hereinafter acquired or solely
developed by Altus relating to the making, using and selling of the Materials, including Altus
Know-How and Altus Patent Rights.

     “Amano Know-How” means all materials and information now owned and hereinafter acquired or
solely developed by Amano relating to the making, using and selling of the Materials.

     “Amano Patent Rights” means all patents and patent applications now owned or controlled or
hereinafter owned or acquired or solely developed by Amano relating to making, using and selling
the Materials.

     “Amano Technology” means any and all technologies now owned and hereinafter acquired or solely
developed by Amano relating to the making, using and selling of the Materials, including Amano
Know-How and Amano Patent Rights.

     “Average Material Cost” means, with respect to a particular [*****] that [*****] of the
Materials, the [*****] to [*****] a [*****] for [*****] to Altus during the [*****].

     “CMO” means any third-party contract manufacturer selected and engaged by Altus to manufacture
all of any portion of the Materials required by Altus for use in the Product.

     “Confidential Information” means (a) all proprietary information and materials, patentable or
otherwise, of a Party which is disclosed by or on behalf of such Party to the other Party,
including cells, substances, formulations, techniques, methodology, equipment, data, reports,
know-how, preclinical and clinical trials and the results thereof, sources of supply, patent
positioning and business plans, including any negative developments, and (b) any other information
designated by the disclosing Party to the other Party as confidential or proprietary, whether or
not related to the use or production of the Product.

     “FDA” means the United States Food and Drug Administration.

     “GMP” means the then-current good manufacturing practice regulations of the as described in
the United States Code of Federal Regulations or any successor regulations.

     . “Improvements” means (a) any technology or information, patentable or otherwise, developed
or acquired by Amano, either solely or jointly with Altus, during the term of this Agreement or the

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-2-

 

Development Agreement in connection with manufacturing the Materials, and (b) any improvement to
the [*****] for the [*****], in each case which is reasonably useful or necessary or is required to
develop, use, and manufacture the Materials.

     “IND” means an Investigational New Drug application or its equivalent or any corresponding
foreign application or registration.

     “Intellectual Property Rights” means Altus Technology, Amano Technology and Joint Technology.

     “Joint Know-How” means all materials and information now owned and hereinafter acquired or
developed by jointly by Altus and Amano relating to the making, using and selling of the Materials.

     “Joint Patent Rights” means all patents and patent applications now owned or controlled or
hereinafter owned, acquired or developed jointly by Altus and Amano relating to making, using and
selling the Materials.

     “Joint Technology” means any and all technologies now owned and hereinafter acquired or
developed jointly by Altus and Amano relating to the making, using and selling of the Materials,
including Joint Know-How and Joint Patent Rights.

     “Marketing Approval” the date upon which the FDA has approved the Product for sale in the
United States.

     “Materials” means those enzymes used as active ingredients in the Product, which are made up
of selected lipase, protease and amylase and manufactured in accordance with Specifications
approved by Altus, the use, making or manufacturing of which, is covered by a Valid Claim of any of
the Amano Patent Rights or Joint Patent Rights and/or embodies any Amano Know-How or Joint
Know-How.

     “Net Sales” means, with respect to the Product, the gross amount invoiced by Altus or its
Affiliates or sublicensees on sales or other dispositions of such Product to third Parties less the
sum of (a) trade, cash and quantity discounts or rebates actually allowed or taken, (b) credit or
allowances given or made for rejection of or return of, and for uncollectable amounts on,
previously sold Products or for retroactive price reductions (including Medicare and similar types
of rebates), (c) charges for insurance, freight, and other transportation costs directly related to
the delivery of the Products and invoiced by Altus or its Affiliates or sublicensees, (d) sales,
transfer
and other excise taxes levied on the sale or delivery of such Product (including any tax

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-3-

 

such as a
value added or similar tax or government charge) borne by the seller thereof, other than franchise
or income tax of any kind whatsoever, and (e) credits or allowances given or made for wastage
replacement, indigent patient and any other sales programs.

     “NDA” means a New Drug Application or its equivalent or any corresponding foreign application
or registration.

     “Party” means Amano or Altus; “Parties” means Amano and Altus.

     “Product” means Altus’ product, TrizytecTM [porcine-free enzymes], and any and all
formulations, mixtures or compositions thereof which, or the use, making or manufacturing of which,
is covered by a Valid Claim of any of the Amano Patent Rights or Joint Patent Rights and/or
embodies any Amano Know-How or Joint Know-How.

     “Reset Date” means each date ending at the end of the Set Royalty Payment Period and ending
each [*****] period thereafter.

     “Reset Period” means the [*****] period starting on a particular Reset Date.

     “Residual Average Material Cost” means, with respect to a particular enzyme that constitutes
part of the Materials, the [*****] (a) [*****] to [*****] a [*****] for [*****] to Altus and (b)
[*****] by [*****] or its [*****] during the [*****] prior to the applicable [*****].

     “Set Royalty Determination Period” means the period commencing on the date that Altus [*****]
for the Product to [*****] and ending [*****] thereafter. The “Set Royalty Determination Period”
is the period of time over which [*****] is [*****].

     “Set Royalty Payment Period” has the meaning given to it in section 3.1(d).

     “Set Royalty Date” means the date which is the end of the Set Royalty Determination Period.

     “Specifications” means the written specifications developed for the manufacture of the
Materials that are provided by or approved in writing by Altus, as such may be amended from time to
time only with Altus’ prior written approval.

     “Valid Claim” means a claim of an unexpired patent which shall not have been withdrawn,
cancelled or disclaimed, nor held invalid by a court of competent jurisdiction in an unappealed or
unappealable decision, or the claim of a patent application which has not been on file for more
than seven years.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-4-

 

Article II. LICENSE

     2.1. Grant. Subject to the reservation of rights in Section 2.2, Amano hereby grants
to Altus and its Affiliates an exclusive, perpetual, worldwide license under the Amano Technology,
the Joint Technology and any Improvements developed by Amano in each case, with the right to grant
sublicenses and/or assign the foregoing, (a) to manufacture, have manufactured, use, market,
advertise, promote, distribute, offer for sale, sell, export and import the Product, and (b) to
develop, manufacture and have manufactured the Materials for the sole purpose of exercising its
rights under clause (a) of this license. It is contemplated that Altus will sublicense the Amano
Technology and the Joint Technology to one or more CMOs, which shall be [*****] Altus, to enable
such CMO(s) to manufacture Materials for Altus. Altus will [*****] Amano’s [*****] and [*****]
prior to [*****] any [*****] to [*****] Materials and will reasonably consider any [*****] or
[*****] that [*****] may [*****] relating to the [*****]of the [*****]. In addition, it is
anticipated that Altus may enter into a sublicense or collaboration agreement with a third party to
develop and/or commercialize the Product, and that Altus may sublicense the Amano Technology and
the Joint Technology to such third-party in connection with such sublicense or collaboration.

     2.2. Reservation of Rights. Except as set forth in Section 2.3, Amano retains the
right under the Amano Technology and the Joint Technology (a) to manufacture the enzymes that make
up the Materials for the purpose of fulfilling its rights and obligations under this Agreement and
(b) to manufacture and sell the enzymes to third Parties in accordance with Section 2.3.

     2.3 Non-Competing Pharmaceutical Products.

          (a) Amano agrees that it shall not supply to any third party any [*****] from the [*****] of
the [*****] for [*****] supplied under the Development Agreement during the term of this Agreement.

          (b) Amano shall not [*****] any of the [*****] than to [*****] without [*****] from [*****],
provided that nothing herein [*****] any [*****] of [*****] a [*****] with any [*****] or [*****]
manufactured by Amano solely using [*****] and/or other technologies of any third party.

          (c) Notwithstanding the foregoing, Amano shall not [*****]; provided, however, for the
avoidance of doubt, the Parties agree that Amano shall be permitted to market, sell and supply
[*****] provided in each case such enzymes are [*****]; and provided further,
however, Amano shall be permitted to continue supplying the enzymes that it currently supplies to
customers (other than Altus) if, [*****].

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-5-

 

Article III. ROYALTIES

     3.1 Royalties.

          (a) Commencing on the date of this Agreement through the Set Royalty Date, Altus or its
sublicensees shall pay to Amano a royalty equal to [*****] of the [*****] by a [*****]
(excluding [*****] and [*****] to [*****] or [*****] for any [*****] to and [*****] or [*****] for [*****].

          (b) From and after the Set Royalty Date, Altus or its sublicensees shall pay Amano a royalty
of [*****] of the [*****] for each [*****] of [*****] either (a) [*****] by a [*****] to and
[*****] or its [*****] or (b) [*****] by [*****] or [*****] for [*****].

          (c) In the event that any Improvements are developed that [*****] in a [*****] in the [*****],
then Amano shall be entitled to an additional royalty for each [*****] of [*****] (a) [*****] by a
[*****] to and [*****] or [*****] and (b) [*****] by [*****] or [*****] for [*****], in each case
equal to [*****] of the [*****] by which the [*****] as a result of such Improvement. This
additional royalty is in addition to the [*****] royalty of the [*****] prior to implementation of
the improvements provided in Section 3.1(b) above. It is possible that more than one Improvement
may be developed that [*****] in a [*****] in the [*****]; in such case, Amano shall be entitled to
an additional royalty for each such Improvement.

          (d) The royalty payable under Section 3.1(b) hereof shall be payable for a period of [*****]
after Marketing Approval, , provided however, that if a royalty becomes payable under Section
3.1(c), then the [*****] under [*****] for (i) an additional [*****] from the first date of the
implementation of any [*****] Improvement giving rise to the royalty under Section 3.1(c) or (ii)
with respect to [*****] Improvements, for so long as there is a Valid Claim with respect to such
Improvement in [*****] or any [*****] (the “Set Royalty Payment Period”). Thereafter, on each
Reset Date, the parties will determine the [*****], and during the Reset Period starting on such
Reset Date, Altus or its sublicensees shall pay Amano a royalty of [*****] of such [*****] for each
[*****] of [*****] either (a) [*****] by a [*****] to and [*****] or [*****] or (b) [*****] by
[*****] or [*****] for [*****].

     3.2. Reports and Payment. All royalties due hereunder shall be payable in U.S.
Dollars. Altus or its sublicensees shall deliver to Amano within [*****] after the end of each
calendar quarter, a written report showing its computation of royalties due under this Agreement
for such calendar
quarter, based on (a) the [*****] from the [*****] for the [*****] for which a royalty is due
during

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-6-

 

such calendar quarter and (b) the amount of [*****] by [*****] or [*****] for [*****] during
such calendar quarter. If [*****] or [*****] have [*****] for the [*****] in a currency other than
U.S. Dollars, such report shall include the rates of exchange used to convert such payment to
United States dollars from the currency in which the
[*****] for the [*****] were made. For
the purposes hereof, the rates of exchange to be used shall be those in effect for the purchase of
dollars at Citicorp, New York, New York, on the day on which [*****] was [*****] for [*****]. Altus
or its sublicensees, simultaneously with the delivery of each such report, shall tender payment in
United States dollars of all royalties shown to be due thereon.

     3.3 Records. Altus shall keep, and shall require all Affiliates and sublicensees to
keep, full, true and accurate books of accounts and other records containing all information and
data which may be necessary to ascertain and verify the royalties payable hereunder. During the
term of this Agreement and for a period of [*****] following its termination, Amano shall have the
right from time to time (not to exceed [*****] during [*****] to inspect in confidence, or have an
agent, accountant or other representative inspect in confidence, such books, records and supporting
data.

Article IV. AMANO OPTION

     4.1 Option to Supply Commercial and Clinical Materials.

          (a) Amano is hereby granted an option to elect to supply Altus or its sublicensees Materials
for commercial and clinical purposes in an amount up to [*****] at [*****] at [*****] currently
[*****] for [*****], provided that Amano has complied with its obligations under this Agreement,
including without limitation, Articles IV and V of this Agreement. In order to exercise such
option, Amano must notify Altus in writing no later [*****] following [*****] for the Product (the
“Initial Exercise Notice”) of its intent to supply such Materials, and such notice shall include a
statement (a) of which Materials (protease, lipase, and/or amylase) and the quantity of materials
Amano intends to supply and (b) that Amano intends to [*****] its [*****] so that is [*****] for
the [*****] that [*****] that Amano intends to supply at such quantities. Within a reasonable
time following the delivery of the Initial Exercise Notice, Altus will amend its NDA for the
Product to add Amano as a supplier of the Materials.

          (b) At any time between the delivery of the Initial Exercise Notice and [*****], and provided
that Amano has complied with its obligations under this Agreement, including without limitation,
Articles IV and V of this Agreement, if Amano desires to manufacture Materials in addition to those
specified in the Initial Exercise Notice, Amano will give notice (the “Second Notice”) to Altus or
its sublicensees of such desire, together with a plan [*****] or [*****] a [*****] to supply
[*****] that [*****], and the Parties will work together to determine whether
Amano will be a primary or secondary supplier of not less than [*****] of Altus’ or its
sublicensees clinical or

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-7-

 

commercial requirements for such Materials, and the terms upon which Amano
will supply such Materials.

     4.2 [*****]. If Amano exercises the option set forth in Section 4.1 above, the Parties will
work together to develop and agree upon a plan for Amano to [*****] one or more of [*****] or
[*****] a [*****] that is [*****] for the [*****] of [*****] and which will (a) meet Altus’ or its
sublicensees supply requirements and (ii) meet regulatory requirements for a [*****]. This will
include [*****] and [*****]. In addition, in such case, (a) Altus will provide Amano will a
reasonable level of support specified in the plan agreed to by the Parties [*****], including
regulatory support and access to Altus’ regulatory documentation, reasonably needed by Amano to
[*****] and (b) Amano will supply such documentation and a reasonable level of support necessary to
enable Altus or its sublicensees to meet its [*****] to the [*****] that Amano will become a
commercial supplier of the Materials. Amano agrees to allow the FDA to inspect the facility where
the Materials will be manufactured and to cooperate with the FDA regarding such inspection.

     4.3 Long Term Supply Agreement and Quality Agreement. Upon the exercise by Amano of
the option set forth in Section 4.1 above, the Parties will negotiate and enter into a long-term
supply agreement (with respect to the Initial Exercise Notice) or an amendment to such long term
supply agreement (with respect to Material that Parties agree will be supplied under the Second
Notice) that will address usual and customary terms, including the following:

	 	(a)	 	A plan for the [*****] of Amano’s [*****] and a timeline for
the [*****] of [*****] to make [*****] at [*****] (currently estimated to be no
later than [*****] after [*****]).
	 
	 	(b)	 	Minimum/maximum amounts that Amano will be responsible to
supply.
	 
	 	(c)	 	Minimum/maximum amounts that Altus or its sublicensees will be
required to purchase (to be based on the quantity that the Amano facility can
produce, as agreed by the Parties).
	 
	 	(d)	 	That all Materials will be manufactured in accordance with the
Specifications, and any other specifications set forth in any marketing
approval of the NDA (or foreign equivalents in the European Union and
Japan) by the FDA (or foreign equivalents in the European Union and Japan).

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-8-

 

	 	(e)	 	No changes to the Specifications or manufacturing process
[*****] shall be implemented with respect to any Materials ordered by or
delivered to Altus or its sublicensees without Altus’ or its sublicensees prior
written approval.
	 
	 	(f)	 	Forecasting parameters and timing of forecasting of Materials
requirements by Altus.
	 
	 	(g)	 	Allocation of costs incurred in connection with the development
of any process changes required to produce the Materials to be supplied by
Amano.
	 
	 	(h)	 	Pricing for the Materials. It is agreed that the price charged
by Amano for [*****] and [*****] will be [*****] the [*****] by any [*****],
and that the price to be charged for [*****] shall be [*****]. If any
Improvements are developed that reduce the manufacturing cost of the Materials
manufactured by Amano, then, Amano shall notify Altus or its sublicensees of
the amount of the reduction in the manufacturing cost (together with supporting
documentation) and the Parties will negotiate a price reduction for such
Materials, it being intended that the Parties will [*****] in the [*****].
Altus or its sublicensees shall have the right, at its own expense, to audit
Amano’s records upon reasonable notice, to verify the basis and accuracy of
Amano’s calculation of the reduction in manufacturing costs
	 
	 	(i)	 	Any additional work that may be required to assure that
processes and product remain comparable among all of Altus’ manufacturers for
Trizytec having multiple manufacturers supplying the same Materials.
	 
	 	(j)	 	The long-term supply agreement will not become effective until
such time as [*****] and other [*****] in the [*****] has [*****] as [*****] of
the [*****] or the [*****] is otherwise authorized under [*****] and [*****].

In addition, the Parties will negotiate and enter into a customary commercial quality agreement
that satisfies the GMP quality standards applicable to the commercial supply of the Materials.

Article V. SUPPORT

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-9-

 

     5.1 CMO and Technology Transfer Support. Amano will cooperate with Altus and its
sublicensees regarding technology transfer to any CMO selected by Altus or its sublicensees,
it being acknowledged that technology transfer to Lonza, Ltd., has
already commenced. Promptly after the Effective Date, the Parties will work together to develop a technology
transfer plan pursuant to which Amano will provide Altus and its current CMO, Lonza, Ltd. with
reasonable technology transfer support. From time to time, the Parties may modify such plan to
effect any changes reasonably required by Altus. Each party shall [*****] to effect its
obligations under the technology transfer plan in accordance with such plan’s terms, milestones,
and/or timelines. Altus shall reimburse Amano for its reasonable costs (including travel expenses
and personnel costs at the FTE rate set forth on Exhibit A) in implementing the technology transfer
plan. Altus may request Amano to provide, and Amano shall provide reasonable technology transfer
support to Altus or any other CMO or sublicense that may in the future manufacture the Materials on
terms to be agreed by the Parties.

     5.2 Support for NDA Submission. Promptly after the Effective Date, the Parties will
work together to develop a regulatory support plan pursuant to which Amano will provide Altus or
its sublicensees with reasonable support regarding Amano’s past and future manufacture of the
Materials for Altus’ planned NDA submission to the FDA. Such support shall include the items
listed on Exhibit B. From time to time, the Parties may modify such plan to effect any changes
reasonably required by Altus. Each party shall [*****] to effect its obligations under the
regulatory support plan in accordance with such plan’s terms, milestones, and/or timelines. Altus
shall reimburse Amano for its reasonable costs (including travel expenses and personnel costs at
the FTE rate set forth on Exhibit A) in implementing the regulatory support plan. In addition,
Amano will provide Altus with access to manufacturing process development data reasonably required
for the submission and approval of the NDA.].

     5.3 Support for Raw Material Sourcing. At Altus’ request, and if Amano agrees, the
Parties will work together to develop a work plan pursuant to which Amano will assist Altus or its
sublicensees in identifying and testing secondary or alternative sources of raw materials for the
Materials or obtaining Japanese sources for such raw materials. From time to time, the Parties may
modify such plan to effect any changes reasonably required by Altus. Each party shall [*****] to
effect its obligations under such work plan in accordance with such plan’s terms, milestones,
and/or timelines. Altus shall reimburse Amano for its reasonable costs (including travel expenses
and personnel costs at the FTE rate set forth on Exhibit A) in implementing the regulatory support
plan.

     5.4 [*****]. The Parties will work together to develop a [*****] plan not later than [*****]
pursuant to which Amano will perform work to improve the [*****] and the [*****] for the
[*****]. From time to time, the Parties may modify such plan to effect any changes reasonably
required by Altus. It is agreed that Amano will perform the work, and that Altus will provide
oversight and input. Alternatively, the Parties may agree to have a third-party perform the
necessary

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-10-

 

work at Altus’ expense. Each party shall [*****] to effect its obligations under the
[*****] plan in accordance with such plan’s terms, milestones, and/or timelines. Altus shall
reimburse Amano for its reasonable costs (including travel expenses and personnel costs at the FTE
rate set forth on Exhibit A) in implementing the [*****] plan. In addition, Amano will properly
[*****] the [*****] for the [*****] under [*****] and enable the use of the [*****], if reasonably
necessary, for any required testing or for new [*****].

     5.5 Additional Development Work. At Altus’ request, and if Amano agrees, the Parties
will work together to develop a work plan pursuant to which Amano will perform additional
development work regarding the Materials. From time to time, upon mutual agreement of the Parties,
the Parties may modify such plan to effect any changes reasonably requested by Altus. Each party
shall [*****] to effect its obligations under such work plan in accordance with such plan’s terms,
milestones, and/or timelines. Altus shall reimburse Amano for its reasonable costs (including
travel expenses and personnel costs at the FTE rate set forth on Exhibit A) in implementing any
such development work plan.

     5.5 Invoices and Payment. Amano shall invoice Altus for all costs for which Amano is
entitled to reimbursement pursuant to Sections 5.1, 5.2, 5.3, 5.4 and 5.5, and all undisputed
payments will be made by Altus within [*****] of its receipt of an invoice. If any portion of an
invoice is disputed, Altus shall pay the undisputed portion of such invoice, and the Parties shall
use good faith efforts to reconcile the disputed amount as soon as practicable. All amounts due
hereunder shall be payable in U.S. Dollars

Article VI. INTELLECTUAL PROPERTY RIGHTS

     6.1. Ownership of Technology. AMANO shall own the entire right, title and interest in
and to all Amano Technology. Altus shall own the entire right, title and interest in and to all
Altus Technology. The Parties shall jointly own the entire right, title and interest in and to all
Joint Technology. It is hereby acknowledged and agreed that the [*****] and the [*****] for the
[*****] constitute [*****], and that any [*****] or [*****] to the [*****] or [*****] for the
[*****] will be [*****] by Altus, its Affiliates and sublicensees [*****] the [*****] of the
[*****] and not for [*****] agreed to in writing by [*****].

Without [*****],[*****], its [*****] and [*****] shall not [*****] or [*****] the [*****] or
[*****] by way of [*****], or by [*****] causing [*****] thereto, and shall not [*****] any [*****]
to do the same.. In addition, [*****], its [*****] and [*****] shall be also [*****] from
[*****] to [*****] any [*****], and shall not [*****] any [*****] to [*****] to [*****] any
[*****], which are different, whether in [*****] or otherwise, from the [*****] that should have
been [*****] if [*****], its [*****] and [*****] had not [*****] or [*****] the [*****] or [*****]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-11-

 

in violation of the preceding sentence. Subject to the preceding sentences, [*****] shall have the
[*****] to [*****] and [*****] the [*****] or any [*****] for regulatory or commercial purposes
(for example, by [*****] or [*****]). Any such [*****] that [*****] an [*****] shall constitute
[*****], subject to the [*****] under [*****].

     6.2. Responsibility for Patenting of Amano Patent Rights and Joint Patent Rights.

          (a) Except as otherwise provided in this Agreement, Amano shall have the right and
responsibility to decide whether or not to seek or continue to seek or maintain patent protection
on any Amano Patent Rights in any country, and shall have the right to file for, procure and
maintain patents on any Amano Patent Rights in any country and shall bear all expenses in
connection therewith. If Amano elects not to seek or continue to seek or maintain patent
protection on any Amano Patent rights in any country, Altus shall have the right, at its expense
but in the name of Amano, to file, procure and maintain in such country or countries as it may
choose on such Amano Patent Rights. Amano agrees to advise Altus of all decisions taken under this
Section 7.3(a) in a timely manner in order to allow Altus to protect its rights hereunder.

          (b) Except as otherwise provided in this Agreement, the Parties shall jointly decide whether
or not to seek or continue to seek or maintain patent protection on any Joint Patent Rights in any
country whether to file for, procure and maintain patents on any Joint Patent Rights in any country
and shall bear equally all expenses in connection therewith, provided, however, that if there is a
disagreement, then either party may seek or maintain patent protection on the Joint Patent Rights
at its own expense but in the name of both Parties. Except as otherwise provided in this
Agreement, [*****] may [*****] or otherwise [*****] in any [*****] to [*****] without the prior
written consent of [*****]. Except for [*****] permitted under this Agreement, in case [*****]
desires to [*****] its [*****], the [*****] shall be [*****] to [*****] as [*****] between the
Parties in good faith. Furthermore, except as otherwise provided herein, if [*****] proposes to
[*****] a [*****] to [*****], such Party shall [*****] the [*****] of the [*****] to such [*****].

          (c) Each Party shall provide the other Party with copies of all substantive communications
from all patent offices regarding applications or patents on any Amano Patent Rights and Joint
Patent Rights promptly after the receipt thereof. Each Party shall provide the other Party with
copies of all proposed substantive communications to such patent offices regarding applications or
patents on any Amano Patent Rights and joint Patent Rights in sufficient time before the due date
in order to enable the other Party an opportunity to comment on the content thereof.

          (d) Each Party shall make available to the other Party or its authorized attorneys, agents or
representatives, such of its employees whom the other Party in its reasonable judgment deems
necessary in order to assist it in obtaining patent protection for the Amano Patent Rights and

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-12-

 

the
Joint Patent Rights. Each Party shall sign or use [*****] to have signed all legal documents
necessary to file and prosecute patent applications or to obtain or maintain patents at no cost to
the other Party.

          6.3. Infringement.

          (a) Each Party shall promptly report in writing to the other Party during the term of this
Agreement any (i) known infringement or suspected infringement of any of the Amano Patent Rights or
the Joint Patent Rights, or (ii) unauthorized use or misappropriation of Amano Know-How or Joint
Know-How by a third party of which it becomes aware, and shall provide the other Party with all
available evidence supporting said infringement, suspected infringement or unauthorized use or
misappropriation.

          (b) Except as provided in subsection (d) below, Altus shall have the right to initiate an
infringement or other appropriate suit anywhere in the world against any third party who at any
time has infringed, or is suspected of infringing, any of the Amano Patent Rights or joint Patent
Rights or of using without proper authorization all or any portion of the Amano Know-How or the
Joint Know-How in connection with the making, using or sale of products that compete with the
Product. Altus shall give Amano sufficient advance notice of its intent to file said suit and the
reasons therefor, and shall provide Amano with an opportunity to make suggestions and comments
regarding such suit. Altus shall keep Amano promptly informed, and shall from time to time consult
with Amano regarding the status of any such suit and shall provide Amano with copies of all
documents filed in, and all written communications relating to, such suit.

          (c) Altus shall have the sole and exclusive right to select counsel for any suit referred to
in subsection (b) above and shall pay all expenses of the suit, including without limitation
attorneys’ fees and court costs. Altus and/or its Affiliates shall be entitled to retain [*****]%
of any damages, royalties, settlement fees or other consideration for past infringement resulting
therefrom, and Amano shall be entitled to receive [*****]% of any such damages, royalties,
settlement fees or other consideration. If necessary, Amano shall join as a party to the suit but
shall be under no obligation to participate except to the extent that such participation is
required as the result of being a named party to the suit. Amano shall offer reasonable assistance
to Altus in connection therewith at no charge to Altus except for reimbursement of reasonable
out-of-pocket expenses incurred in rendering such assistance. Amano shall have the right to
participate and be represented in any such suit by its own counsel at its own expense. Altus shall
not settle any such suit involving rights of Amano without obtaining the prior written consent of
Amano, which consent shall not be unreasonably withheld.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-13-

 

          (d) In the event that Altus elects not to initiate an infringement or other appropriate suit
pursuant to subsection (b) above, Altus shall promptly advise Amano of its intent not to initiate
such suit, and Amano shall have the right, at the expense of Amano, of initiating an infringement
or other appropriate suit against any third party who at any time has infringed, or is suspected of
infringing, any of the Amano Patent Rights or Joint Patent Rights or of using without proper
authorization all or any portion of the Amano Know-How or Joint Know-How in connection with the
making, using or sale of products that compete with the Product. In exercising its rights pursuant
to this subsection (d), Amano shall have the sole and exclusive right to select counsel and shall,
except as provided below, pay all expenses of the suit including without limitation attorneys’ fees
and court costs. Amano shall be entitled to [*****] its [*****] from any damages, royalties,
settlement fees or other consideration for [*****] resulting therefrom, and thereafter Altus and/or
its Affiliates shall be entitled to retain [*****]% of any remaining damages, royalties, settlement
fees or other consideration, and Amano shall be entitled to receive [*****]% of any remaining
damages, royalties, settlement fees or other consideration. If necessary, Altus shall join as a
party to the suit but shall be under no obligation to participate except to the extent that such
participation is required as a result of being a named party to the suit. At Amano’s request,
Altus shall offer reasonable assistance to Amano in connection therewith at no charge to Amano
except for reimbursement of reasonable out-of-pocket expenses incurred in rendering such
assistance. Altus shall have the right to participate and be represented in any such suit by its
own counsel at its own expense.

     6.4. Claimed Infringement.

          (a) In the event that a third party at any time provides written notice of a claim to, or
brings an action, suit or proceeding against, either Party or any of their respective Affiliates or
sublicensees, claiming infringement of its patent rights or unauthorized use or misappropriation of
its know-how, based upon an assertion or claim arising out of the development, use, manufacture,
distribution or sale of the Materials or the Product, such Party shall promptly notify the other
Party of the claim or the commencement of such action, suit or proceeding, enclosing a copy of the
claim and/or all papers served. Amano agrees to make available to Altus its advice and counsel
regarding the technical merits of any such claim at no cost to Altus.

          (b) If Altus or its Affiliates, in order to operate under or exploit the licenses granted
under Article II of this Agreement in any country, must make payments (including without limitation
royalties, option fees or license fees) to one or more third Parties to obtain a license or similar
right in the absence of which the Amano Technology could not legally be used in connection with the
manufacture, development, use, filling and finishing, distribution or sale of the Materials or the
Product in any country in the world, Altus may deduct from royalties thereafter
payable to Amano an amount equal to up to [*****] of such
third party payments, provided that the total royalties otherwise due to Amano for any Materials
shall not be reduced by more than [*****] as a result of such deduction.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-14-

 

          (c) THE FOREGOING STATES THE ENTIRE RESPONSIBILITY OF AMANO IN THE CASE OF ANY CLAIMED
INFRINGEMENT OR VIOLATION OF ANY THIRD PARTY’S RIGHTS OR UNAUTHORIZED USE OR MISAPPROPRIATION OF
ANY THIRD PARTY’S KNOW-HOW.

     6.5 Intellectual Property Developed Prior to the Effective Date. It is agreed that
the ownership and responsibility for the patenting of any intellectual property developed by the
Parties (a) prior to the Effective Date shall be governed by the provisions of the Development
Agreement, and (b) after the Effective Date shall be governed by the provisions of this Agreement.

Article VII. CONFIDENTIAL INFORMATION

     7.1. Treatment of Confidential Information. Each Party hereto shall maintain the
Confidential Information of the other Party in confidence, and shall not disclose, divulge or
otherwise communicate such Confidential Information to others, or use it for any purpose, except
pursuant to, and in order to carry out, the terms and objectives of this Agreement, and hereby
agrees to exercise every reasonable precaution to prevent and restrain the unauthorized disclosure
of such Confidential Information by any of its directors, officers, employees, consultants,
subcontractors, sublicensees or agents. This provision applies to any Confidential Information
disclosed or developed under the Development Agreement.

     7.2. Release from Restrictions. The provisions of Section 7.1 shall not apply to any
Confidential Information disclosed hereunder which:

          (a) was known or used by the receiving Party or its Affiliates prior to its date of disclosure
to the receiving Party, as evidenced by the prior written records of the receiving Party or its
Affiliates; or

          (b) either before or after the date of the disclosure to the receiving Party is lawfully
disclosed to the receiving Party or its Affiliates by an independent, unaffiliated third party
rightfully in possession of the Confidential Information; or

          (c) either before or after the date of the disclosure to the receiving Party becomes published
or generally known to the public through no fault or omission on the part of the receiving Party or
its Affiliates.

In addition, the receiving Party may disclose Confidential Information pursuant to the requirement
of a governmental agency or any law requiring disclosure thereof, provided that the receiving

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-15-

 

Party
gives the disclosing Party prompt and reasonable notification of such requirement prior to such
disclosure, if possible, in order to enable the disclosing Party to take such actions as it deems
appropriate to obtain confidential treatment for such disclosure and to minimize the extent of such
disclosure

Article VIII. TERMINATION

     8.1. Term. This Agreement shall remain in effect until terminated in accordance with
the provisions of this Article IX.

     8.2. Termination for Breach. Each Party shall be entitled to terminate this Agreement
and the licenses granted hereunder to the other Party by written notice to the other Party in the
event that the other Party shall be in material default of any of its obligations hereunder, and
shall fail to remedy any such default within [*****] after notice thereof by the non-breaching
Party. Any such notice shall specifically state that the non-breaching Party intends to terminate
this Agreement in the event that the breaching Party shall fail to remedy the default. Upon any
termination of this Agreement pursuant to this Section 8.2, neither Party shall be relieved of any
obligations incurred prior to such termination.

     8.3. Termination for Financial Matters. A Party shall have the right to terminate
this Agreement by written notice immediately upon the occurrence of either of the following: (a)
the entry of a decree or order for relief by a court having jurisdiction in the premises in respect
of the other Party in an involuntary case under any applicable national, federal, or state
insolvency or other similar law, and the continuance of any such decree or order unstayed and in
effect for a period of [*****]; or (b) the filing by the other Party of a petition for relief under
any applicable national, federal, or state insolvency or other similar law.

     8.4. Effect of Termination. Survival of Obligations; Return of Confidential
Information.

          (a) In case of termination of this Agreement: (i) by Amano for Altus’s material breach; or
(ii) by Altus for reasons other than Amano’s material breach, Altus shall retain a perpetual,
worldwide, royalty bearing license, for so long as the Products are sold, with right to sublicense,
to Amano Technology and Joint Technology, to make, have made, use, sell, offer to sell and import
Materials employing such Amano Technology and Joint Technology. The royalty rate shall be [*****]
of Net Sales of the Products.

          (b) In case of termination of this Agreement: by Altus for Amano’s material breach;, Altus
shall retain a perpetual, worldwide, non-royalty bearing license, for so long as the Products are
sold, with right to sublicense, to Amano Technology and Joint Technology, to make,

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-16-

 

have made, use,
sell, offer to sell and import Materials and Products employing such Amano Technology and Joint
Technology.

          (c) Notwithstanding any termination of this Agreement, the obligations of the Parties under
Article VII and Sections 6.4 and 8.1, as well as under any other provisions which by their nature
are intended to survive any such termination, shall survive and continue to be enforceable. Upon
any termination of this Agreement pursuant to Section 9.2 hereof, each Party shall promptly return
to the other Party all written Confidential Information, and all copies thereof, of the other Party
which is not covered by a license surviving such termination.

Article 1X. INDEMNIFICATION AND LIABILITY LIMITATIONS

     9.1. Product Liability Indemnification. Altus agrees to defend Amano, its agents,
directors, officers and employees, at Altus’s sole expense, and will indemnify and hold harmless
Amano, its agents, directors, officers and employees, from and against any and all product
liability losses, costs, damages, fees or expenses arising out or in connection with Altus’s or any
of its Affiliate’s or sublicensee’s manufacture, use or sale of any Product arising out of any
actual or alleged injury, damage, death or other consequence occurring to any person as a result,
directly or indirectly, of the possession, use or consumption of any Product, whether claimed by
reason of breach of warranty, negligence, product defect or otherwise, and regardless of the form
in which any such claim is made. In the event of any such claim against Amano or any agent,
director, officer or employee, Amano shall promptly notify Altus in writing of the claim and Altus
shall manage and control, at its sole expense, the defense of the claim and its settlement. Amano
shall cooperate with Altus and may, at its option and expense, be represented in any such action or
proceeding. Altus shall not be liable for any litigation costs or expenses incurred by Amano
without Altus’s written authorization.

     9.2 Limitation of Liability. EXCEPT WITH RESPECT TO BREACH OF THEIR
OBLIGATIONS OF CONFIDENTIALITY UNDER SECTION 7 AND THE OBLIGATION OF INDEMNIFICATION PURSUANT TO
SECTION 9.1, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES WHICH MAY ARISE IN CONNECTION WITH THE EXECUTION AND/OR PERFORMANCE OF THIS
AGREEMENT.

Article X. EXPORT

     10.1. Acknowledgment. The Parties acknowledge that the export of technical data,
materials or products is subject to the exporting Party receiving the necessary export licenses and
that the Parties cannot be responsible for any delays attributable to export controls which are
beyond

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-17-

 

the reasonable control of either Party. The Parties agree that regardless of any disclosure
made by the Party receiving an export of an ultimate destination of any technical data, materials
or products, the receiving Party will not re-export either directly or indirectly, any technical
data, material or products without first obtaining any necessary governmental approvals, including,
if applicable, the applicable validated or general license from the United States Department of
Commerce, FDA and/or any other agency or department of the United States Government, as required.
The receiving Party shall provide the exporting Party with any information, materials,
certifications or other documents which may be reasonably required in connection with such exports
under the Export Administration Act of 1979, as amended, its rules and regulations, the Federal
Food, Drug and Cosmetic Act and other applicable export laws.

Article XI. MISCELLANEOUS

     11.1. Publicity. Neither Party, nor any of its Affiliates, shall originate any
publicity, news release or other public announcement, written or oral, relating to this Agreement
or the existence of an arrangement between the Parties, without the prior written approval of the
other Party, which approval shall not be unreasonably withheld, except as otherwise required by
law.

     11.2. Assignment. Except as otherwise provided in this Agreement, neither this
Agreement nor any of the rights or obligations hereunder may be assigned by either Party without
the prior written consent of the other Party, except to a party who acquires all or substantially
all of the business of the assigning Party to which this Agreement relates by merger, sale of
assets or otherwise.

     11.3. Applicable Law and Arbitration.

          (a) This Agreement shall in all events and for all purposes be governed by, and be construed
in accordance with, the laws of the [*****], without regard to any choice of law principle that
would dictate the application of the law of another jurisdiction.

          (b) The Parties shall attempt in good faith to resolve any dispute arising out of or relating
to this Agreement promptly by negotiation between executives who have authority to settle the
controversy. Any party may give the other party written notice of any dispute not resolved in the
normal course of business. Within [*****] after delivery of the disputing party’s notice, the
executives of both Parties shall meet at a mutually acceptable time and place, and
thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-18-

 

          (c) Any dispute arising out of or relating to this Agreement or the breach, termination or
validity thereof which has not been resolved by a non-binding procedure as provided in Section
11.3(b) above within [*****] of the initiation of such procedure, shall be settled by arbitration
in accordance with the CPR Non-Administered International Arbitration Rules in effect on the date
of this Agreement (the “Rules”) (http://www.cpradr.org/) by three independent and impartial
arbitrators, of whom each party shall appoint one, and a third arbitrator, who shall chair the
tribunal, shall be appointed in accordance with Rule 5.2. The third arbitrator shall not be a
national of either country of the Parties.

          (d) Notwithstanding Section 11.3(a) above, the judgment upon the award rendered by the
arbitrators may be entered by any court having jurisdiction thereof.

          (e) The place of arbitration shall be [*****]. The neutral organization designated to perform
the functions specified in Rule 6 and Rules 7.7(b), 7.8 and 7.9 shall be the CPR.

          (f) The statute of limitations of [*****] applicable to the commencement of a lawsuit shall
apply to the commencement of an arbitration hereunder.

          (g) The procedures specified in this Section 11.3 shall be the sole and exclusive procedures
for the resolution of disputes between the Parties arising out of or relating to this Agreement;
provided, however, that a party, without prejudice to the above procedures, may seek a preliminary
injunction or other provisional judicial relief if in its sole judgment such action is necessary to
avoid irreparable damage or to preserve the status quo. Despite such action the Parties will
continue to participate in good faith in the procedures specified in this Section 11.3

          (h) All applicable statutes of limitation and defenses based upon the passage of time shall be
tolled while the procedures specified in this Section 11.3 are pending. The Parties will take such
action, if any, required to effectuate such tolling.

          (i) Each party is required to continue to perform its obligations under this Agreement pending
final resolution of any dispute arising out of or relating to this Agreement, unless to do so would
be impossible or impracticable under the circumstances

     11.4. Force Majeure. In the event that either Party is prevented from performing or
is unable to perform any of its obligations under this Agreement due to any act of God; fire;
casualty; flood; war; strike; lockout; failure of public utilities; injunction or any act,
exercise, assertion or requirement of governmental authority; epidemic; destruction of production
facilities; riots;

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-19-

 

insurrection; inability to procure or use materials, labor, equipment,
transportation or energy; or any other cause beyond the reasonable control of the Party invoking
this Section 11.4 if such Party shall have used its best efforts to avoid such occurrence, such
Party shall give notice to the other Party in writing promptly, and thereupon the affected Party’s
performance shall be excused and the time for performance shall be extended for the period of delay
or inability to perform due to such occurrence.

     11.5. Waiver. The waiver by either Party of a breach or a default of any provision of
this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of
the same or any other provision, nor shall any delay or omission on the part of either Party to
exercise or avail itself of any right, power or privilege that it has or may have hereunder operate
as a waiver of any right, power or privilege by such Party.

     11.6. Notices. Any notice or other communication in connection with this Agreement
must be in writing and if by mail, by certified mail, return receipt requested, or by express
courier service providing evidence of receipt and shall be effective when delivered to the
addressee at the address listed below or such other address as the addressee shall have specified
in a notice actually received by the addressor.

If to AMANO:

AMANO Enzyme, Inc.

1-2-7, Nishiki, Naka-ku

Nagoya, Japan

Attention: President

If to Altus:

640 Memorial Drive

Cambridge, MA 02492

USA

Attention: Vice President, Strategic Planning and Alliance Management

With copies to (a) General Counsel and (b) Vice President, Process Development and Engineering at
the same address.

     11.7. No Agency. Nothing herein shall be deemed to constitute either Party as the
agent or representative of the other Party, or both Parties as joint venturers or partners for any
purpose. Amano shall be an independent contractor, not an employee or partner of Altus, and the
manner in which Amano renders its services under this Agreement shall be within Amano’s sole
discretion.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-20-

 

Neither Party shall be responsible for the acts or omissions of the other Party, and
neither Party will have authority to speak for, represent or obligate the other Party in any way
without prior written authority from the other Party.

     11.8. Entire Agreement. This Agreement and the Exhibits hereto (which Exhibits are
deemed to be a part of this Agreement for all purposes) contain the full understanding of the
Parties with respect to the subject matter hereof and supersede all prior understandings and
writings relating thereto, including the Development Agreement; provided, however, that the
following provisions of the Development Agreement shall survive to the extent not expressly
superceded hereby: Article 5.1, Article 5.2 of the Development Agreement and Sections 1 and 4 of
Amendment No. 2 to Cooperative Development Agreement dated March 16, 2007. In addition, the
quality agreement referenced in Section 5 of the Amendment to Cooperative Development Agreement
dated October 11, 2005 shall continue in full force and effect with respect to any activities
undertaken or materials manufactured under the Development Agreement. For the avoidance of doubt,
the Development Agreement shall survive and continue in effect solely with respect to the
activities, rights and obligations pertaining to ALTU-237 under Amendment No. 3. No waiver,
alteration or modification of any of the provisions hereof shall be binding unless made in writing
and signed by the Parties by their respective officers thereunto duly authorized.

     11.9. Headings. The headings contained in this Agreement are for convenience of
reference only and shall not be considered in construing this Agreement.

     11.10. Severability. In the event that any provision of this Agreement is held by a
court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any
law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected,
and the rights and obligations of the Parties shall be construed and enforced as if the Agreement
did not contain the particular provisions held to be unenforceable.

     11.11 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or
pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of
Section 365(n) of the Bankruptcy Code licenses of rights of “intellectual property” as defined in
Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of
their respective rights and elections under the Bankruptcy Code. Upon the bankruptcy of any Party,
the non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to,
any such intellectual property, and such, if not already in its possession, shall be
promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and
continues, to perform all of its obligations under this Agreement

     11.12. Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the Parties hereto and their successors and permitted assigns.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-21-

 

     11.13. Third Parties. None of the provisions of this Agreement shall be for the
benefit of or enforceable by any third party.

     11.14 Language. This Agreement is in the English language only, which language shall
control and any version in any other language shall be for accommodation only and shall not bind
the Parties hereto.

     11.15. Counterparts. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original but all of which together shall constitute one and the
same instrument.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-22-

 

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as a sealed
instrument in their names by their properly and duly authorized officers or representatives as of
the date first above written.

	 	 	 	 	 	 	 	 	 	 	 
	AMANO ENZYME, INC.	 	 	 	ALTUS PHARMACEUTICALS INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Motoyuki Amano
	 	 	 	By:
	 	/s/ Robert Gallotto	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Name:

	 	Motoyuki Amano
	 	 	 	Name:
	 	Robert Gallotto	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Title:

	 	President
	 	 	 	Title:
	 	Vice President, Strategic Planning	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

-23-

 

EXHIBIT A

FTE Rate

Amano’s FTE rate on a per diem basis shall be $[*****] per day (currently ¥[*****]). If Amano
expends less than eight (8) hours per day, a pro-rata charge shall apply. Such rate shall be
[*****], commencing in [*****], by the [*****] in the [*****] for the previous year.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

 

 

EXHIBIT B

Regulatory Support

Pre-NDA (next 12 months)

	 	•	 	Detailed development report: [*****]

	 	o	 	[*****] selected the [*****]: e.g., [*****] chosen based on x years
manufacturing experience for [*****], etc.
	 
	 	o	 	[*****] rationale: e.g., [*****] to [*****] to [*****] production,
which then [*****] to [*****] such as x,y,z..
	 
	 	o	 	Changes in process may be due to variables such as historical data vs.
new data obtained, availability of equipment

	 	•	 	Detailed Development report: [*****]

	 	o	 	See above for examples

	 	•	 	Detailed Development Report: [*****]

	 	o	 	See above for examples

	 	•	 	[*****]: may require assistance accessing/compiling data
	 
	 	•	 	Long-term pre-approval inspection readiness (if necessary)

 

	*	 	Refer to ICH Pharmaceutical Development section of ICH Guideline for

The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality
— M4Q(R1) for detailed content requirements (Section 3.2.P.2).
http://www.ich.org/LOB/media/MEDIA556.pdf

NDA

	 	•	 	NDA support

	 	o	 	Review of documents for NDA (both [*****] and [*****])
	 
	 	o	 	Review of [*****] as follows:

[*****] which include:

          [*****]

Post-NDA submission/Pre-approval

	 	o	 	Participation on rapid response team involvement — to [*****] from [*****] as soon as possible to
avoid [*****]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE

SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION

REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE EXCHANGE ACT.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]